347 related articles for article (PubMed ID: 34964438)
1. Hepatic
Lee YH; Jang HJ; Kim S; Choi SS; Khim KW; Eom HJ; Hyun J; Shin KJ; Chae YC; Kim H; Park J; Park NH; Woo CY; Hong CH; Koh EH; Nam D; Choi JH
Elife; 2021 Dec; 10():. PubMed ID: 34964438
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect.
Yan F; Wang Q; Xu C; Cao M; Zhou X; Wang T; Yu C; Jing F; Chen W; Gao L; Zhao J
PLoS One; 2014; 9(6):e99245. PubMed ID: 24926685
[TBL] [Abstract][Full Text] [Related]
3. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function.
Wang X; Wang J; Ying C; Xing Y; Su X; Men K
BMC Pharmacol Toxicol; 2024 Jan; 25(1):7. PubMed ID: 38173037
[TBL] [Abstract][Full Text] [Related]
5. Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α.
Cui S; Pan XJ; Ge CL; Guo YT; Zhang PF; Yan TT; Zhou JY; He QX; Cheng LH; Wang GJ; Hao HP; Wang H
Chin J Nat Med; 2021 Jun; 19(6):401-411. PubMed ID: 34092291
[TBL] [Abstract][Full Text] [Related]
6. Aberrant miR199a-5p/caveolin1/PPARα axis in hepatic steatosis.
Li B; Zhang Z; Zhang H; Quan K; Lu Y; Cai D; Ning G
J Mol Endocrinol; 2014 Dec; 53(3):393-403. PubMed ID: 25312970
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
Huang R; Duan X; Liu X; Cao H; Wang Y; Fan J; Wang B
Biochem Biophys Res Commun; 2019 Jan; 508(4):1252-1258. PubMed ID: 30558790
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of hepatic CLOCK by PPARα is involved in inhibition of NAFLD.
Luo J; Yan Z; Dai M; Xu L; Zhang H; Xi Y; Yang J; Liu A
J Mol Med (Berl); 2023 Feb; 101(1-2):139-149. PubMed ID: 36527474
[TBL] [Abstract][Full Text] [Related]
9. PPARα is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD.
Xu Y; Wang M; Luo Y; Liu H; Ling H; He Y; Lu Y
J Ethnopharmacol; 2024 Apr; 323():117684. PubMed ID: 38171466
[TBL] [Abstract][Full Text] [Related]
10. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.
Chen J; Chen J; Fu H; Li Y; Wang L; Luo S; Lu H
Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E710-E722. PubMed ID: 31430204
[TBL] [Abstract][Full Text] [Related]
12. Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.
Mahmoudi A; Butler AE; Jamialahmadi T; Sahebkar A
Biomed Res Int; 2021; 2021():3654660. PubMed ID: 34988225
[TBL] [Abstract][Full Text] [Related]
13. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity.
Cao YN; Yue SS; Wang AY; Xu L; Hu YT; Qiao X; Wu TY; Ye M; Wu YC; Qi R
J Ethnopharmacol; 2022 Jun; 292():115146. PubMed ID: 35304272
[TBL] [Abstract][Full Text] [Related]
14. Potential involvement of PPAR α activation in diminishing the hepatoprotective effect of fenofibrate in NAFLD: Accuracy of non- invasive panel in determining the stage of liver fibrosis in rats.
Hamed AM; El-Kharashi OA; Boctor SS; Abd-Elaziz LF
Biomed Pharmacother; 2017 Jan; 85():68-78. PubMed ID: 27930988
[TBL] [Abstract][Full Text] [Related]
15. Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.
Jiang S; Uddin MJ; Yu X; Piao L; Dorotea D; Oh GT; Ha H
Diabetes Metab J; 2022 Nov; 46(6):829-842. PubMed ID: 35746892
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.
Lalloyer F; Wouters K; Baron M; Caron S; Vallez E; Vanhoutte J; Baugé E; Shiri-Sverdlov R; Hofker M; Staels B; Tailleux A
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1573-9. PubMed ID: 21474829
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes.
Wang XY; Lu LJ; Li YM; Xu CF
Life Sci; 2022 Nov; 308():120925. PubMed ID: 36057399
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic role of Artemether in the prevention of hepatic steatosis through miR-34a-5p/PPARα pathway.
Chen L; Yu S; Hong S; Lin X; Zhu X; Cao X; Li Y; Xiao H
Drug Dev Res; 2023 Apr; 84(2):156-171. PubMed ID: 36541217
[TBL] [Abstract][Full Text] [Related]
19. MiR-192-5p Ameliorates Hepatic Lipid Metabolism in Non-Alcoholic Fatty Liver Disease by Targeting
Ma L; Song H; Zhang CY; Hou D
Biomolecules; 2023 Dec; 14(1):. PubMed ID: 38254634
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease.
Xu M; Zheng XM; Jiang F; Qiu WQ
J Cell Biochem; 2018 Jul; 119(7):5864-5874. PubMed ID: 29575055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
